EAPC Position Statement states that exercise programs for diabetics are a cost effective treatment and should be reimbursed.

In patients at high CV risk, higher absolute event rates were seen across the RHR spectrum in those with diabetes, but the relative risk increase based on RHR was similar for those with and without diabetes.

In the SACRA study, treatment with empagliflozin for 12 weeks was associated with reductions from baseline in nighttime, clinic, 24-hour ABP and morning HBP in T2DM with uncontrolled nocturnal hypertension.

This is a summary of the presentation by prof. Stephan Jacob, in which he talked about the management of diabetes, focusing on the shift from glucose to CV risk management in patients with diabetes.

This is a summary of the presentation by prof. Nikolaus Marx, in which he addressed the mode of action of SGLT2 inhibitors, and presented clinical outcome data and potential mechanisms.

CME accredited course focussed on the role of SGLT2 inhibitors in the management of patients with Diabetic Kidney Disease. Member registration (free) is needed to enroll in this course

A posthoc analysis of the LEADER trial showed that liraglutide showed more pronounced CV benefits in T2DM patients aged 75 years or older, than in those between 60 and 74 years of age.

CME accredited course focussed on how new developments with antidiabetic drugs will impact the management of CVD. Member registration (free) is needed to enroll in this course

A post-hoc analysis showed reduced LDL-c levels and improved lipid profiles up to 180 days with one or two doses of inclisiran on top of standard care in the presence and absence of diabetes, compared to placebo.

Different GLP-1RAs have shown different effects in CV outcomes trials. Prof Rydén scrutinizes the results of the trials to learn more about the effects of individual GLP-1RAs and what the differences may originate from.

Expert Consensus Decision Pathways are meant to complement guidelines and bridge remaining gaps in clinical guidance, in this case the use of SGLT2 inhibitors and GLP-1RAs to lower CV risk in T2DM.

In a phase 2b randomized trial, LY3298176, a dual GIP and GLP-1 RA, led to a statistically significant and clinically meaningful dose-dependent improvement of glucose lowering and body weight reduction compared with dulaglutide.